The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Takeaway Message from the NSABP-47 Trial in HER2-low Breast Cancer

Mothaffar F. Rimawi, MD
Published Online: 10:23 PM, Wed December 6, 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.